Treatment of Oligometastatic Disease
Mary-Ellen Taplin, MD, discusses the evolving treatment landscape for oligometastatic prostate cancer.
Read MoreSelect Page
Posted by Mary-Ellen Taplin, MD | Mar 2025
Mary-Ellen Taplin, MD, discusses the evolving treatment landscape for oligometastatic prostate cancer.
Read MorePosted by John Sylvester, MD, FABS | Mar 2025
John Sylvester, MD, FABS, delves into the historical evolution, techniques, and efficacy of brachytherapy in prostate cancer management.
Read MorePosted by David G. Bostwick, MD, MBA, FCAP | Mar 2025
David G. Bostwick, MD, MBA, FCAP, discusses the potential of intratumoral immunotherapy in treating prostate cancer.
Read MorePosted by Alan H. Bryce, MD | Mar 2025
Alan H. Bryce, MD, delves into the critical role of genetic testing in prostate cancer management.
Read MorePosted by Nelson N. Stone, MD | Feb 2025
Nelson N. Stone, MD, balances the radiation dose and hormonal therapy in managing intermediate- and high-risk prostate cancer.
Read More